GGrantIndex
← Leaderboards

Ralph Mazitschek

Massachusetts General Hospital

$5,975,673
Attributed
$8,662,778
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY201224
$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$8,662,778 · 4

By mechanism

R01$5,374,211 · 2
P50$2,818,317 · 1
R21$470,250 · 1

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Regulation

Research focus

RegulationIn VivoBaseBiochemicalMolecularBiologyProtein IsoformsReportingGeneticResponseNovel TherapeuticsMapsSynthesis ChemistrySmall MoleculeInhibitor/AntagonistMediatingTechnologyPreventionDesignGenome-WidePreventGenesCell PhysiologyMalignant Neoplasms

Grant awards (16)

Proline homeostasis: a novel mediator of drug tolerance in Plasmodium falciparum$699,605
R01 · FY2024 · AI · contact PI
Proline homeostasis: a novel mediator of drug tolerance in Plasmodium falciparum$699,605
R01 · FY2023 · AI · contact PI
Proline homeostasis: a novel mediator of drug tolerance in Plasmodium falciparum$699,605
R01 · FY2022 · AI · contact PI
Proline homeostasis: a novel mediator of drug tolerance in Plasmodium falciparum$643,981
R01 · FY2021 · AI · contact PI
Proline homeostasis: a novel mediator of drug tolerance in Plasmodium falciparum$657,600
R01 · FY2020 · AI · contact PI
Chemical Optoepigenetic Regulation of Chromatin-Mediated Neuroplasticity$394,763
R01 · FY2018 · NS · contact PI
Inhibitor class dependent consequences of prolyl-tRNA synthetase inhibition in Plasmodium falciparum$213,750
R21 · FY2018 · AI · contact PI
Chemical Optoepigenetic Regulation of Chromatin-Mediated Neuroplasticity$394,763
R01 · FY2017 · NS · contact PI
Inhibitor class dependent consequences of prolyl-tRNA synthetase inhibition in Plasmodium falciparum$256,500
R21 · FY2017 · AI · contact PI
Chemical Optoepigenetic Regulation of Chromatin-Mediated Neuroplasticity$394,763
R01 · FY2016 · NS · contact PI
Imaging Histone Decatelylase (HDAC) Inhibition in Cancer$713,549
P50 · FY2015 · CA · contact PI
Chemical Optoepigenetic Regulation of Chromatin-Mediated Neuroplasticity$394,763
R01 · FY2015 · NS · contact PI
Imaging Histone Decatelylase (HDAC) Inhibition in Cancer$694,779
P50 · FY2014 · CA · contact PI
Chemical Optoepigenetic Regulation of Chromatin-Mediated Neuroplasticity$394,763
R01 · FY2014 · NS · contact PI
Imaging Histone Decatelylase (HDAC) Inhibition in Cancer$722,187
P50 · FY2013 · CA · contact PI
Imaging Histone Decatelylase (HDAC) Inhibition in Cancer$687,802
P50 · FY2012 · CA · contact PI